Goldenwell Biotech Q2 2026: Zero Revenue, Cash Down to $11K, Going Concern Doubts Deepen
GWLL has more than doubled off its 52-week low of $0.059 on light trading volume (0.2× avg).
Summary
Goldenwell Biotech's Q2 2026 report shows zero revenue, a $36,876 quarterly loss, and only $11,143 in cash. The company reiterates going concern doubts and needs roughly $5 million to build manufacturing facilities, with no financing arranged.
Key Events · Earnings and Guidance · GWLL
-
Zero Revenue, $36.9K Quarterly Loss
Q2 2026 revenue was $0, with a net loss of $36,876 for the quarter and $54,482 for the six months ended June 30, 2026.
-
Cash Drops to $11,143
Cash fell from $26,775 at year-end 2025 to $11,143 at June 30, 2026. Working capital deficit widened to $398,195.
-
Going Concern Doubts Reiterated
Management again states substantial doubt about the company's ability to continue as a going concern, citing accumulated losses of $1,710,598 and no revenue.
-
CEO Loans Additional $45,000
CEO Shuang Liu loaned the company $15,000 on April 20 and $30,000 on June 30, 2026, bringing total related-party loans to $140,588.
Analysis · GWLL · Manufacturing
With zero revenue for Q2 2026 and a net loss of $36,876, Goldenwell Biotech is left with just $11,143 in cash against $427,173 in total liabilities. The company again states substantial doubt about its ability to continue as a going concern, and its disclosure controls remain ineffective. The CEO loaned the company another $45,000 during the quarter, but that is not enough to fund the estimated $5 million needed to build manufacturing facilities. Without new financing, the business will fail.
At the time of this filing, GWLL was trading at $0.77 on OTC in the Manufacturing sector, with a market capitalization of approximately $76.2M. The 52-week trading range was $0.06 to $10.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.